Talquetamab
Johnson & Johnson Takes Lead in Bispecific Antibody Approval for Multiple Myeloma, Leaving Pfizer in the Dust
SG Tylor
The FDA has granted accelerated approval to talquetamab-tgvs, branded as Talvey, for treating relapsed or refractory multiple myeloma in adults ...
Bispecific Antibodies in Multiple Myeloma: A Combination Leads to Durable Responses
SG Tylor
Bispecific antibodies in multiple myeloma are a new class of drugs that can target two different antigens at the same ...
